NVCT Nuvectis Pharma Inc
Price (delayed)
$9.46
Market cap
$221.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.11
Enterprise value
$202.75M
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock
Highlights
NVCT's EPS is up by 22% year-on-year and by 4.3% since the previous quarter
The net income has grown by 15% YoY
NVCT's quick ratio is down by 24% year-on-year and by 24% since the previous quarter
The equity has contracted by 20% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of NVCT
Market
Valuations
Earnings
Shares outstanding
23.39M
Market cap
$221.28M
Enterprise value
$202.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
18.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.85M
Net income
-$19M
EBIT
-$19M
EBITDA
-$19M
Free cash flow
-$12.25M
Per share
Balance sheet
Liquidity
EPS
-$1.11
EPS diluted
-$1.11
Free cash flow per share
-$0.72
Book value per share
$0.5
Revenue per share
$0
TBVPS
$1.09
Total assets
$18.61M
Total liabilities
$8.89M
Debt
$0
Equity
$9.71M
Working capital
$9.71M
Debt to equity
0
Current ratio
2.09
Quick ratio
2.08
Net debt/EBITDA
0.98
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-102.8%
Return on equity
-160.8%
Return on invested capital
N/A
Return on capital employed
-195.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCT stock price
How has the Nuvectis Pharma stock price performed over time
Intraday
1.18%
1 week
8.11%
1 month
41.41%
1 year
19.14%
YTD
74.86%
QTD
-3.17%
Financial performance
How have Nuvectis Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.85M
Net income
-$19M
Gross margin
N/A
Net margin
N/A
The net income has grown by 15% YoY
The operating income rose by 13% year-on-year and by 2.1% since the previous quarter
Growth
What is Nuvectis Pharma's growth rate over time
Valuation
What is Nuvectis Pharma stock price valuation
P/E
N/A
P/B
18.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVCT's EPS is up by 22% year-on-year and by 4.3% since the previous quarter
NVCT's P/B is 81% higher than its last 4 quarters average of 10.3
The equity has contracted by 20% YoY and by 12% from the previous quarter
Efficiency
How efficient is Nuvectis Pharma business performance
The ROE has contracted by 11% YoY and by 3.2% from the previous quarter
The ROA has increased by 4.6% YoY
Dividends
What is NVCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCT.
Financial health
How did Nuvectis Pharma financials performed over time
Nuvectis Pharma's total assets is 109% more than its total liabilities
The total liabilities has increased by 41% since the previous quarter and by 27% year-on-year
Nuvectis Pharma's current ratio has decreased by 24% YoY and by 24% from the previous quarter
NVCT's debt is 100% lower than its equity
The equity has contracted by 20% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.